Losing participants before the trial ends erodes credibility of findings
dc.contributor.author | Xia, Jun | |
dc.contributor.author | Adams, Clive E. | |
dc.date.accessioned | 2017-10-30T11:08:23Z | |
dc.date.available | 2017-10-30T11:08:23Z | |
dc.date.issued | 2009 | |
dc.identifier.citation | Xia, J., Adams, C. E., Bhagat, N., Bhagat, V., Bhoopathi, P., El-Sayeh, H., Pinfold, V. & Takriti, Y. (2009). Losing participants before the trial ends erodes credibility of findings. Psychiatric Bulletin, 33 (7), pp.254-257. | en |
dc.identifier.other | 10.1192/pb.bp.108.021949 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12904/9776 | |
dc.description.abstract | AIMS AND METHOD: To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers. RESULTS: We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70-75% for the trial to be credible. CLINICAL IMPLICATIONS: This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this. | |
dc.description.uri | https://www.cambridge.org/core/journals/psychiatric-bulletin/article/losing-participants-before-the-trial-ends-erodes-credibility-of-findings/8ECF898917C72AFF772E758874C198B7 | |
dc.subject | Schizophrenia | en |
dc.subject | Clinical trial | en |
dc.title | Losing participants before the trial ends erodes credibility of findings | en |
dc.type | Article | |
html.description.abstract | AIMS AND METHOD: To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers. RESULTS: We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70-75% for the trial to be credible. CLINICAL IMPLICATIONS: This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this. |